<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988036</url>
  </required_header>
  <id_info>
    <org_study_id>WSG-AM09</org_study_id>
    <secondary_id>2018-003996-37</secondary_id>
    <nct_id>NCT03988036</nct_id>
  </id_info>
  <brief_title>A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)</brief_title>
  <acronym>Keyriched-1</acronym>
  <official_title>A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NanoString Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keyriched-1 is a multicenter, interventional, prospective, single arm, open label,&#xD;
      neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced&#xD;
      by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab&#xD;
      biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular&#xD;
      HER2-enriched intrinsic subtype tested by PAM50.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HER2-positive breast cancer is best defined by multiparameter gene expression profiling&#xD;
      rather than analysis of the overexpression/amplification status of only HER2. As this&#xD;
      subgroup is often correlated with a high expression of TILs and PD/PD-L1, immunogenic therapy&#xD;
      strategies seem very promising. The pCR highly correlates with the overall outcome of&#xD;
      patients with HER2-positive breast cancer [7]. Therefore, the pCR rate after neoadjuvant&#xD;
      treatment has been adopted as a surrogate endpoint and, more recently, as a basis for&#xD;
      accelerated drug approval [38].&#xD;
&#xD;
      Due to the high number of patients achieving a pCR after standard treatment of anti-HER2&#xD;
      therapy combined with chemotherapy, de-escalated strategies seem promising and designing a&#xD;
      chemotherapy-free trial regimen is therefore modern, justifiable and of high scientific&#xD;
      value. Therefore, we designed a prospective phase II, single arm, hypothesis-generating trial&#xD;
      investigating the rate of pCR in patients with HER2-enriched breast cancer receiving four&#xD;
      cycles of dual anti-HER2 blockade in combination with the checkpoint inhibitor pembrolizumab.&#xD;
      Further translational research will be added to gain further insight into the tumor response&#xD;
      or resistance to this treatment approach. The addition of standard chemotherapy after this&#xD;
      study treatment will be at the discretion of the investigator. In case of a non-pCR after&#xD;
      study treatment, continuing treatment with chemotherapy and antihormonal therapy in case of&#xD;
      HR positive disease is highly recommended.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-HER2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with HER2-enriched early breast cancer assessed by PAM50 testing</measure>
    <time_frame>After neoadjuvant treatment (planned duration of treatment is 12 weeks)</time_frame>
    <description>pCR defined as no invasive tumor in breast and lymph nodes (ypT0/is, ypN0) at surgery after study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of fatal adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>AEs classified by System Organ Class (SOC) and Preferred Terms (PT), descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of serious treatment-emergent adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>AEs classified by System Organ Class (SOC) and Preferred Terms (PT), descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of treatment-related adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>AEs classified by System Organ Class (SOC) and Preferred Terms (PT), descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of treatment-emergent adverse events of interest as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>AEs classified by System Organ Class (SOC) and Preferred Terms (PT), descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of adverse events leading to investigational product discontinuation</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>AEs classified by System Organ Class (SOC) and Preferred Terms (PT), descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of severity of adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>Descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of causality of adverse events as assessed by investigator and sponsor</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>Descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of outcome of adverse events as per investigator assessment</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>Descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of seriousness of adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>9 months for individual participants</time_frame>
    <description>Descriptive analysis by number of observations and their percentage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2-enriched</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.&#xD;
Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product&#xD;
Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.&#xD;
Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.&#xD;
Route: Intravenous infusion.&#xD;
Schedule: Every 3 weeks during the neoadjuvant phase.&#xD;
Pertuzumab (Perjeta®) - Investigational Medicinal Product&#xD;
Loading dose: 840 mg, initial administration.&#xD;
Maintenance dose: 420 mg.&#xD;
Route: Intravenous infusion.&#xD;
Schedule: Every 3 weeks during the neoadjuvant phase.&#xD;
Pembrolizumab (Keytruda®) - Investigational Medicinal Product&#xD;
Dose: 200 mg.&#xD;
Route: Intravenous infusion.&#xD;
Schedule: Every 3 weeks during the neoadjuvant phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intravenous infusion; 200 mg; every 3 weeks</description>
    <arm_group_label>HER2-enriched</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Biosimilar ABP 980</intervention_name>
    <description>Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks</description>
    <arm_group_label>HER2-enriched</arm_group_label>
    <other_name>Trazimera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks</description>
    <arm_group_label>HER2-enriched</arm_group_label>
    <other_name>Perjeta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants, who are at least 18 years of age on the day of signing informed&#xD;
             consent with newly histologically locally confirmed diagnosis of HER2neu 2+ or 3+&#xD;
             breast cancer.&#xD;
&#xD;
          -  Have previously untreated, non-metastatic (M0) HER2-enriched breast cancer defined as&#xD;
             the following combined primary tumor (T) and regional lymph node (N) staging per&#xD;
             American Joint Committee on Cancer (AJCC) for breast cancer staging criteria version 7&#xD;
             as assessed by the Investigator based on radiological and/or clinical assessment:&#xD;
&#xD;
        T1c, N0-N2; T2, N0-N2; T3, N0-N2&#xD;
&#xD;
          -  Patients with HER2-enriched, estrogen and/ or progesterone receptor positive or&#xD;
             negative breast cancer defined by American Society of Clinical Oncology (ASCO) /&#xD;
             College of American Pathologists (CAP) guidelines can be included.&#xD;
&#xD;
          -  Availability of tumor imaging performed within three months prior to start of&#xD;
             screening phase: breast ultrasound and computed tomography (CT) thorax/abdomen or&#xD;
             chest X-ray/liver ultrasound, bone scan, mammography or breast magnetic resonance&#xD;
             imaging (MRI) (according to local standard).&#xD;
&#xD;
          -  Ability to provide archived tumor tissue sample or at least two newly obtained&#xD;
             separate tumor cores from the primary tumor or excisional biopsy of a tumor lesion not&#xD;
             previously irradiated at screening to the central laboratory. Formalin-fixed, paraffin&#xD;
             embedded (FFPE) tissue blocks are preferred over slides. Newly obtained biopsies are&#xD;
             preferred over archived tissue.&#xD;
&#xD;
        Note: If submitting unstained cut slides, newly cut slides should be submitted to the&#xD;
        testing laboratory within 14 days from the date slides are cut.&#xD;
&#xD;
        Patients are eligible to be included in the trial only if all of the following criteria&#xD;
        apply [items 1-6 must be met by the patient to be enrolled into the trial and before the&#xD;
        start of the screening phase]:&#xD;
&#xD;
          1. Female patients, who are at least 18 years of age on the day of signing informed&#xD;
             consent, with newly histologically locally confirmed diagnosis of HER2neu 2+ or 3+&#xD;
             breast cancer.&#xD;
&#xD;
          2. Previously untreated, non-metastatic (M0) HER2-enriched breast cancer defined as the&#xD;
             following combined primary tumor (T) and regional lymph node (N) staging per AJCC for&#xD;
             breast cancer staging criteria version 7 as assessed by the investigator based on&#xD;
             radiological and/or clinical assessment:&#xD;
&#xD;
               -  T1c, N0-N2;&#xD;
&#xD;
               -  T2, N0-N2;&#xD;
&#xD;
               -  T3, N0-N2.&#xD;
&#xD;
          3. Patients with HER2-enriched, estrogen and/or progesterone receptor-positive or&#xD;
             -negative breast cancer defined by ASCO/CAP guidelines.&#xD;
&#xD;
          4. Availability of tumor imaging performed within three months prior to start of&#xD;
             screening phase: breast ultrasound and CT thorax/abdomen or chest X-ray/liver&#xD;
             ultrasound, bone scan, mammography or breast MRI (according to local standard).&#xD;
&#xD;
          5. Ability to provide an archived tumor tissue sample or at least two newly obtained&#xD;
             separate tumor cores from the primary tumor or excisional biopsy of a tumor lesion not&#xD;
             previously irradiated at screening to the central laboratory. Formalin-fixed, paraffin&#xD;
             embedded (FFPE) tissue blocks are preferred over slides. Newly obtained biopsies are&#xD;
             preferred over archived tissue.&#xD;
&#xD;
             Note: If submitting unstained cut slides, newly cut slides should be submitted to the&#xD;
             testing laboratory within 14 days from the date slides are cut.&#xD;
&#xD;
          6. A female patient is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
             and if at least one of the following conditions applies:&#xD;
&#xD;
               1. not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR&#xD;
&#xD;
               2. a WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the&#xD;
                  treatment period and for at least 7 months after the last dose of study treatment&#xD;
                  Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
                  contraception for the patient.&#xD;
&#xD;
          7. The patient provides written informed consent for participation in the trial. The&#xD;
             patient may also provide consent for future biomedical research. However, the patient&#xD;
             may participate in the main trial without participating in future biomedical research.&#xD;
&#xD;
          8. Confirmed HER2neu (IHC 2+ status and amplification [e.g. by FISH] or IHC 3+ status)&#xD;
             tumor identification by local pathology.&#xD;
&#xD;
          9. Confirmed HER2-enriched status by PAM50 testing.&#xD;
&#xD;
         10. Confirmed HR+ or HR- status.&#xD;
&#xD;
         11. Female patients of childbearing potential must have a negative urine or serum&#xD;
             pregnancy test within 72 hours prior to receiving the first dose of study medication.&#xD;
             If the urine test is positive or borderline, a serum pregnancy test will be required.&#xD;
&#xD;
             Note: In the event that 72 hours have elapsed between the screening pregnancy test and&#xD;
             the first dose of study treatment, another pregnancy test (urine or serum) must be&#xD;
             performed and must be negative in order for the patient to start receiving study&#xD;
             medication.&#xD;
&#xD;
         12. Left ventricular ejection fraction (LVEF) of ≥55% or ≥ institution lower limit of&#xD;
             normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA)&#xD;
             scan performed at screening or performed in clinical routine within 6 weeks prior to&#xD;
             first treatment allocation.&#xD;
&#xD;
         13. Normal ECG performed at screening or performed in clinical routine within 6 weeks&#xD;
             prior to first treatment allocation.&#xD;
&#xD;
         14. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of&#xD;
             ECOG performance status is to be performed within 10 days prior to the date of&#xD;
             treatment initiation.&#xD;
&#xD;
         15. Adequate organ function as defined in the following table. Specimens must be collected&#xD;
             within 10 days prior to the start of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Patients are excluded from the trial if any of the following criteria apply:&#xD;
&#xD;
          1. Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent&#xD;
             or with an agent directed to another stimulatory or co-inhibitory T cell receptor&#xD;
             (e.g. CTLA-4, OX 40, CD137) or has participated in MK-3475 clinical trials.&#xD;
&#xD;
          2. Patient has received prior systemic anti-cancer therapy including investigational&#xD;
             agents within 4 weeks prior to first dose of study medication.&#xD;
&#xD;
             Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1&#xD;
             or baseline. Patients with ≤Grade 2 neuropathy may be eligible.&#xD;
&#xD;
             Note: If the patient received major surgery, they must have recovered adequately from&#xD;
             the toxicity and/or complications from the intervention prior to starting study&#xD;
             treatment.&#xD;
&#xD;
          3. Patient has received a live vaccine within 30 days prior to the first dose of study&#xD;
             drug. Examples of live vaccines include, but are not limited to, the following:&#xD;
             measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,&#xD;
             Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for&#xD;
             injection are generally killed virus vaccines and are allowed; however, intranasal&#xD;
             influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
          4. Patient is currently participating in or has participated in a trial of an&#xD;
             investigational agent or has used an investigational device within 4 weeks prior to&#xD;
             the first dose of study treatment.&#xD;
&#xD;
             Note: Patients who have entered the follow-up phase of an investigational trial may&#xD;
             participate as long as it has been 4 weeks after the last dose of the previous&#xD;
             investigational agent. Patient should be excluded if she received an investigational&#xD;
             agent with anti-cancer or anti-proliferative intent within the last 12 months.&#xD;
&#xD;
          5. Patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid&#xD;
             therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form&#xD;
             of immunosuppressive therapy within 7 days prior to the first dose of study drug.&#xD;
&#xD;
          6. Prior malignancy with a disease-free survival of ≤5 years before signing informed&#xD;
             consent.&#xD;
&#xD;
             Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or carcinoma in situ (e.g. ductal carcinoma in situ, cervical cancer in situ)&#xD;
             that have undergone potentially curative therapy are not excluded.&#xD;
&#xD;
          7. Patient has a known hypersensitivity to the components of the study therapy, its&#xD;
             analogs, murine proteins or any of the excipients.&#xD;
&#xD;
          8. Patient has active autoimmune disease that has required systemic treatment in the past&#xD;
             2 years (i.e. with use of disease-modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment.&#xD;
&#xD;
          9. Patient has a significant cardiovascular disease, such as:&#xD;
&#xD;
               -  LVEF &lt;55%&#xD;
&#xD;
               -  History of myocardial infarction, acute coronary syndrome or coronary&#xD;
                  angioplasty/stenting/bypass grafting within the past 6 months&#xD;
&#xD;
               -  Congestive heart failure (CHF) New York Heart Association (NYHA) Class I-IV or&#xD;
                  history of CHF NYHA class III or IV&#xD;
&#xD;
         10. Severe and relevant co-morbidity that would interact with the application of cytotoxic&#xD;
             agents or the participation in the trial, including but not confined to:&#xD;
&#xD;
               -  Unstable arrhythmias requiring treatment, i.e., atrial tachycardia with a heart&#xD;
                  rate ≥100/min at rest, significant ventricular arrhythmia (ventricular&#xD;
                  tachycardia) or higher-grade AV-block&#xD;
&#xD;
               -  Angina pectoris within the last 6 months requiring anti-anginal medication&#xD;
&#xD;
               -  Clinically significant valvular heart disease&#xD;
&#xD;
               -  Evidence of myocardial infarction on electrocardiogram (ECG)&#xD;
&#xD;
               -  Poorly controlled hypertension (e.g. systolic &gt;180 mm Hg or diastolic &gt;100 mm&#xD;
                  Hg).&#xD;
&#xD;
         11. Inadequate organ function including but not confined to:&#xD;
&#xD;
               -  hepatic impairment (Child Pugh Class C)&#xD;
&#xD;
               -  pulmonary disease (severe dyspnea at rest due to complications of advanced&#xD;
                  malignancy or requiring oxygen therapy).&#xD;
&#xD;
         12. Patient has a history of (non-infectious) pneumonitis that required steroids or has&#xD;
             current pneumonitis.&#xD;
&#xD;
         13. Patient has an active infection requiring systemic therapy.&#xD;
&#xD;
         14. Patient has a known history of human immunodeficiency virus (HIV), hepatitis B&#xD;
             (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as&#xD;
             detectable HCV RNA [qualitative] is detected).&#xD;
&#xD;
             Note: Testing of hepatitis B is required in all patients during screening as standard&#xD;
             of care according to current guidelines in early breast cancer.&#xD;
&#xD;
             HIV and hepatitis C testing is required in all patients with significant risk factors&#xD;
             (see checklist below). There is a significant risk if one of the items on the&#xD;
             checklist applies for the patient.&#xD;
&#xD;
               -  HIV and hepatitis C risk checklist:&#xD;
&#xD;
               -  Patient has frequently changing sexual partners.&#xD;
&#xD;
               -  Patient practices anal sex.&#xD;
&#xD;
               -  The patient has already been diagnosed with another sexually transmitted&#xD;
                  infection, such as syphilis or gonorrhea.&#xD;
&#xD;
               -  Patient suffers from drug abuse.&#xD;
&#xD;
               -  Tattoos or piercings abroad within the last 4 months.&#xD;
&#xD;
               -  Presence of a positive HIV and/or Hepatitis C test.&#xD;
&#xD;
               -  Patient received a blood transfusion before 1992.&#xD;
&#xD;
               -  Patient is an organ transplant recipient.&#xD;
&#xD;
               -  The patient's mother has/had HIV and/or hepatitis C.&#xD;
&#xD;
               -  Patient has elevated liver blood values (relevant for hepatitis C risk).&#xD;
&#xD;
         15. Patient has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
         16. Patient has a history or current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the trial, interfere with the patient's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         17. Patient has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         18. Patient is pregnant or breastfeeding, or expecting to conceive children or planning to&#xD;
             breastfeed within the projected duration of the trial, starting with the screening&#xD;
             visit through 7 months after end of treatment.&#xD;
&#xD;
         19. Male patients with breast cancer.&#xD;
&#xD;
         20. History of breast cancer.&#xD;
&#xD;
         21. Factors indicating risk of poor compliance.&#xD;
&#xD;
         22. Pathological laboratory assessments:&#xD;
&#xD;
               -  Thrombocytopenia &gt; CTCAE grade 1&#xD;
&#xD;
               -  Increases in ALT/AST &gt; CTCAE grade 1&#xD;
&#xD;
               -  Hypokalemia &gt; CTCAE grade 1&#xD;
&#xD;
               -  Neutropenia &gt; CTCAE grade 1&#xD;
&#xD;
               -  Anemia &gt; CTCAE grade 1&#xD;
&#xD;
         23. Non-operable breast cancer including inflammatory breast cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>s.kuemmel@kem-med.com Kuemmel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinics Essen-Mitte, Breast Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherko Kuemmel, Professor</last_name>
    <phone>+4920117433001</phone>
    <email>s.kuemmel@kem-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcel Tahlheim</last_name>
    <phone>+4921615662313</phone>
    <email>marcel.tahlheim@wsg-online.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Department für Frauengesundheit</name>
      <address>
        <city>Tübingen</city>
        <state>BaWü</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf, Prof. Dr. med.</last_name>
      <phone>+49 707-1029822211</phone>
      <email>andreas.hartkopf@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Emily Irslinger</last_name>
      <phone>+49 707-01982203</phone>
      <email>emily.irslinger@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Hartkopf, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva-MAria Grischke, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum, LMU Klinikum, Ludwig-Maximilians-Universität,</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Harbeck, Prof. Dr. med.</last_name>
      <email>nadia.harbeck@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Farangis Stahl</last_name>
      <phone>+49-89-440054170</phone>
      <email>farangis.stahl@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Raquel Würstlein, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Harbeck, PRof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotkreuz Klinikum München</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Braun, Prof. Dr. med.</last_name>
      <phone>+49 89 130330</phone>
      <email>michael.braun@swmbrk.de</email>
    </contact>
    <contact_backup>
      <last_name>Harry Reisch</last_name>
      <phone>+49 89 13033662</phone>
      <email>harry.reisch@swmbrk.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Braun, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claus Hanusch, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Brustzentrum&quot;</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Thill, Prof. Dr. med.</last_name>
      <phone>+49 69 95332228</phone>
      <email>marc.thill@fdk.info</email>
    </contact>
    <contact_backup>
      <last_name>Madeleine Modrow, MSc</last_name>
      <phone>+49 69 9533 0</phone>
      <email>madeleine.modrow@fdk.info</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Thill, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiane Brandi, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken Franziskus-Hospital</name>
      <address>
        <city>Georgsmarienhütte</city>
        <state>Niedersachsen</state>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Lüdtke-Heckenkamp, Dr. med.</last_name>
      <phone>+49 541 5022466</phone>
      <email>jost.wamhoff@niels-stensen-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Jost Wamhoff, Dr. med.</last_name>
      <phone>+49 541 5022466</phone>
      <email>jost.wamhoff@niels-stensen-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Kerstin Lüdtke-Heckenkamp, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jost Wamhoff, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Diakovere Henriettenstift Frauenklinik&quot;</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Kentsch, Dr. med.</last_name>
      <phone>+49 511 2893455</phone>
      <email>angela.kentsch@diakovere.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Anolke</last_name>
      <phone>+49 511 2893455</phone>
      <email>sabine.anolke@diakovere.de</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Kentsch, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Kathrin Gillenberg, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte, Klinik für Senologie/Interdisziplinäres Brustzentrum</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherko Kuemmel, Prof. Dr</last_name>
      <phone>+49-201-17433005</phone>
      <email>s.kuemmel@kliniken-essen-mitte.de</email>
    </contact>
    <contact_backup>
      <last_name>Dorothea Schindowski</last_name>
      <phone>+49-201-17433005</phone>
      <email>d.schindowski@kliniken-essen-mitte.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sherko Kuemmel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mattea Reinisch, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Krankenhaus GmbH</name>
      <address>
        <city>Koeln</city>
        <state>NRW</state>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gertrud Helling-Giese, Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Susanne Brandner, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gertrud Helling-Giese, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für gynäkologische Onkologie am Ev. Krankenhaus Bethesda</name>
      <address>
        <city>Moenchengladbach</city>
        <state>NRW</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleg Gluz, PD Dr</last_name>
      <phone>+49-2161-9811154</phone>
      <email>oleg.gluz@brustzentrum-rhein-ruhr.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Siebmanns</last_name>
      <phone>+49-2161-9813577</phone>
      <email>kathrin.siebmannsn@brustzentrum-rhein-ruhr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raquel von Schumann, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleg Gluz, PD Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Scheffen, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Überörtliche Berufsausübungsgemeinschaft Dr. H. Forstbauer, C. Ziske, R. Reihs, E. Rodermann, A. Diel</name>
      <address>
        <city>Troisdorf</city>
        <state>NRW</state>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Ziske, PD Dr. med.</last_name>
      <phone>+49 2241 3974660</phone>
      <email>ziske@onkologie-rheinsieg.de</email>
    </contact>
    <contact_backup>
      <last_name>Petra Bois@onkologie-rheinsieg.de</last_name>
      <phone>+49 2241 397566877</phone>
      <email>bois@onkologie-rheinsieg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Carsten Ziske, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Diel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl-Gustv-Carus, Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theresa Link, Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Theresa Link, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Wimberger, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Lübeck, Brustzentrum</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nana Bündgen, Dr. med.</last_name>
      <phone>+49 451</phone>
    </contact>
    <investigator>
      <last_name>Nana Bündgen, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henriette Princk, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, CCM; Klinik f. Gynäkologie m. S. Senologie / Brustzentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Blohmer, Prof. Dr.med.</last_name>
      <phone>+49 30 450564172</phone>
      <email>Jens.blohmer@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Joerg Spahrbier</last_name>
      <phone>+49 30 450664297</phone>
      <email>joerg.spahrbier@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jens Blohmer, Prof. Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cornelia Kolberg-Liedtke, Prof. Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ev. Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochem Potenberg, Dr. med.</last_name>
      <phone>+49 30</phone>
    </contact>
    <investigator>
      <last_name>Bjoern Beurer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochem Potenberg, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mammazentrum HH am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Hilpert, Prof. Dr. med.</last_name>
      <phone>+49 40 44190671</phone>
      <email>hilpert@mammazentrum.eu</email>
    </contact>
    <contact_backup>
      <last_name>Silke Kassner</last_name>
      <phone>+49 40 44190557</phone>
      <email>kassner@mammazentrum.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Hilpert, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Schem, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR positive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Early breast cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Anti-HER2 therapy</keyword>
  <keyword>Pertuzumab</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Immune checkpoint inhibitor</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL-1</keyword>
  <keyword>PAM50</keyword>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

